261 related articles for article (PubMed ID: 18405187)
1. Bexarotene monotherapy for epidermotropic CD8+ CTCL.
Kamstrup M; Gniadecki R
Dermatol Clin; 2008 Jan; 26 Suppl 1():45-7. PubMed ID: 18405187
[No Abstract] [Full Text] [Related]
2. Long-term bexarotene monotherapy in large cell CD30+ pleomorphic T-cell lymphoma.
Aldaoud A
Dermatol Clin; 2008 Jan; 26 Suppl 1():15-7. PubMed ID: 18405181
[No Abstract] [Full Text] [Related]
3. CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature.
Gopaluni S; Perzova R; Abbott L; Farah R; Shrimpton A; Hutchison R; Poiesz BJ
Am J Hematol; 2008 Sep; 83(9):744-6. PubMed ID: 18615708
[TBL] [Abstract][Full Text] [Related]
4. About the cutaneous targets of bexarotene in CTCL patients.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e299-301. PubMed ID: 19845753
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
6. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland.
Väkevä L; Ranki A; Hahtola S
Acta Derm Venereol; 2012 May; 92(3):258-63. PubMed ID: 22678563
[TBL] [Abstract][Full Text] [Related]
7. Evolution of clinical and molecular responses to bexarotene treatment in cutaneous T-cell lymphoma.
Ballanger F; Nguyen JM; Khammari A; Dréno B
Dermatology; 2010; 220(4):370-5. PubMed ID: 20484880
[TBL] [Abstract][Full Text] [Related]
8. Bexarotene gel: a new skin-directed treatment option for cutaneous T-cell lymphomas.
Martin AG
J Drugs Dermatol; 2003 Apr; 2(2):155-67. PubMed ID: 12852367
[TBL] [Abstract][Full Text] [Related]
9. Combination treatment modalities in cutaneous T-cell lymphoma (CTCL).
Guitart J
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S17-20. PubMed ID: 16516671
[TBL] [Abstract][Full Text] [Related]
10. The optimal use of bexarotene in cutaneous T-cell lymphoma.
Gniadecki R; Assaf C; Bagot M; Dummer R; Duvic M; Knobler R; Ranki A; Schwandt P; Whittaker S
Br J Dermatol; 2007 Sep; 157(3):433-40. PubMed ID: 17553039
[TBL] [Abstract][Full Text] [Related]
11. Topical and oral bexarotene.
Schadt CR
Dermatol Ther; 2013; 26(5):400-3. PubMed ID: 24099070
[TBL] [Abstract][Full Text] [Related]
12. Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy.
French LE; Shapiro M; Junkins-Hopkins JM; Vittorio CC; Rook AH
J Am Acad Dermatol; 2001 Dec; 45(6):914-8. PubMed ID: 11712039
[TBL] [Abstract][Full Text] [Related]
13. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion.
Assaf C; Bagot M; Dummer R; Duvic M; Gniadecki R; Knobler R; Ranki A; Schwandt P; Whittaker S
Br J Dermatol; 2006 Aug; 155(2):261-6. PubMed ID: 16882161
[TBL] [Abstract][Full Text] [Related]
14. Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma.
Gormley RH; Hess SD; Anand D; Junkins-Hopkins J; Rook AH; Kim EJ
J Am Acad Dermatol; 2010 Feb; 62(2):300-7. PubMed ID: 19944484
[TBL] [Abstract][Full Text] [Related]
15. Molecular markers associated with clinical response to bexarotene therapy in cutaneous T-cell lymphoma.
Ranki A; Väkevä L; Sipilä L; Krohn K
Acta Derm Venereol; 2011 Sep; 91(5):568-73. PubMed ID: 21547336
[TBL] [Abstract][Full Text] [Related]
16. Optimizing bexarotene therapy for cutaneous T-cell lymphoma.
Whitmore SE
J Am Acad Dermatol; 2004 Sep; 51(3):482; author reply 482-3. PubMed ID: 15338005
[No Abstract] [Full Text] [Related]
17. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
[TBL] [Abstract][Full Text] [Related]
18. Bexarotene monotherapy for patients with refractory Sézary syndrome.
Staib G; Scharffetter-Kochanek K
Dermatol Clin; 2008 Jan; 26 Suppl 1():61-3. PubMed ID: 18405190
[No Abstract] [Full Text] [Related]
19. Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature.
Quéreux G; Saint-Jean M; Peuvrel L; Brocard A; Knol AC; Dréno B
Expert Opin Pharmacother; 2013 Sep; 14(13):1711-21. PubMed ID: 23837676
[TBL] [Abstract][Full Text] [Related]
20. Bexarotene monotherapy for patients with advanced stage mycosis fungoides.
Bachelez H
Dermatol Clin; 2008 Jan; 26 Suppl 1():25-6. PubMed ID: 18405183
[No Abstract] [Full Text] [Related]
[Next] [New Search]
